Bernard Davitian
Director/Board Member at LEXEO THERAPEUTICS, INC.
Bernard Davitian active positions
Companies | Position | Start | End |
---|---|---|---|
LEXEO THERAPEUTICS, INC. | Director/Board Member | 2020-10-31 | - |
Independent Dir/Board Member | 2020-10-31 | - | |
Vanqua Bio, Inc.
Vanqua Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Vanqua Bio, Inc. engages in the provision of technology services. The company was founded in 2019 and is headquartered in Chicago, IL. | Director/Board Member | 2021-07-31 | - |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | Private Equity Investor | 2019-12-31 | - |
Career history of Bernard Davitian
Former positions of Bernard Davitian
Companies | Position | Start | End |
---|---|---|---|
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Director/Board Member | 2021-09-30 | 2023-06-29 |
Sanofi Ventures
Sanofi Ventures Investment ManagersFinance Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts. | Chief Executive Officer | 2012-10-31 | 2019-09-30 |
Private Equity Investor | 2012-10-31 | 2019-09-30 | |
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Director of Finance/CFO | 2005-12-31 | 2010-12-30 |
Private Equity Investor | 2005-12-31 | 2010-12-30 | |
Neurotech Pharmaceuticals, Inc. (United States)
Neurotech Pharmaceuticals, Inc. (United States) Pharmaceuticals: MajorHealth Technology Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI. | Chief Executive Officer | 2005-12-30 | 2005-12-31 |
Director of Finance/CFO | 2001-10-31 | - | |
Fortel Invest Oy
Fortel Invest Oy Investment ManagersFinance Fortel Invest Oy (Fortel Invest) is a private equity subsidiary of Sipila Family founded in 1995 by Juha Sipila. The firm is headquartered in Oulu, Finland. | Director of Finance/CFO | 1999-12-31 | 2001-12-30 |
TRANSGENE | Director of Finance/CFO | 1994-12-31 | 1999-12-31 |
░░░░░░ ░░░░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ | ░░░░░░░░░░ | - |
Training of Bernard Davitian
EM Lyon Business School | Graduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Statistics
International
United States | 10 |
France | 6 |
United Kingdom | 2 |
Operational
Director/Board Member | 8 |
Director of Finance/CFO | 6 |
Private Equity Investor | 3 |
Sectoral
Health Technology | 10 |
Commercial Services | 4 |
Finance | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
TRANSGENE | Health Technology |
LEXEO THERAPEUTICS, INC. | Health Technology |
Private companies | 13 |
---|---|
Arthur Andersen LLP
Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL. | Commercial Services |
Neurotech Pharmaceuticals, Inc. (United States)
Neurotech Pharmaceuticals, Inc. (United States) Pharmaceuticals: MajorHealth Technology Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI. | Health Technology |
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Health Technology |
Sanofi Ventures
Sanofi Ventures Investment ManagersFinance Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts. | Finance |
DNA Therapeutics SASU
DNA Therapeutics SASU BiotechnologyHealth Technology DNA Therapeutics SA operates as a clinical stage biopharmaceutical company. It focuses in the research and development of life-saving therapeutics for treatment-resistant cancers. The company was founded by Jian-Sheng Sun and Marie Dutreix in June 2006 and is headquartered in Evry, France. | Health Technology |
Sanofi Pasteur
Sanofi Pasteur BiotechnologyHealth Technology Sanofi Pasteur SA develops, manufactures and supplies vaccines. It provides vaccines for bacterial and viral diseases, including diphtheria, typhoid fever, and poliomyelitis. The company was founded in 1990 and is headquartered in Lyon, France. | Health Technology |
Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
Lysosomal Therapeutics, Inc.
Lysosomal Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lysosomal Therapeutics, Inc. engages in the innovation, research, and development in the field of neurodegeneration. It focuses in lysosomal biology in developing novel small molecules for use in the treatment of neurodegenerative diseases. The company was founded by Dimitri Krainc, Joseph Mazzulli, Henri A. Termeer, Robert J. Carpenter, Peter Wirth, Edmund J. Sybertz, and Kees Cornelis Been in 2011 and is headquartered in Cambridge, MA. | Health Technology |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | Finance |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Commercial Services |
Vanqua Bio, Inc.
Vanqua Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Vanqua Bio, Inc. engages in the provision of technology services. The company was founded in 2019 and is headquartered in Chicago, IL. | Commercial Services |
Fortel Invest Oy
Fortel Invest Oy Investment ManagersFinance Fortel Invest Oy (Fortel Invest) is a private equity subsidiary of Sipila Family founded in 1995 by Juha Sipila. The firm is headquartered in Oulu, Finland. | Finance |
- Stock Market
- Insiders
- Bernard Davitian
- Experience